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Abstract
Alcohol consumption and chronic hepatitis B virus (HBV) infection are two well-established
risk factors for Hepatocellular carcinoma (HCC); however, there remains a limited under-
standing of the molecular pathway behind the pathogenesis and progression behind HCC,
and how alcohol promotes carcinogenesis in the context of HBV+ HCC. Using next-genera-
tion sequencing data from 130 HCC patients and 50 normal liver tissues, we identified a
panel of microRNAs that are significantly dysregulated by alcohol consumption in HBV+
patients. In particular, two microRNAs, miR-944 and miR-223-3p, showed remarkable corre-
lation with clinical indication and genomic alterations. We confirmed the dysregulation of
these two microRNAs in liver cell lines treated by alcohol and acetaldehyde, and showed that
manipulation of miR-223-3p and miR-944 expression induces significant changes in cellular
proliferation, sensitivity to doxorubicin, and the expression of both direct-binding and down-
stream mRNA targets. Together, the results of this study suggest that alcohol consumption in
HBV+ HCCs regulates microRNAs that likely play previously uncharacterized roles in the
alcohol-associated carcinogenesis of HCC, and future studies of these microRNAs may be
valuable for furthering the understanding and treatment of alcohol and HBV-associated HCC.
Introduction
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and the fifth most
deadly cancer, affecting over 500,000 people worldwide every year [1, 2]. One well-established
risk factor for HCC is chronic Hepatitis B (HBV) infection, which accounts for approximately
50% of all cases [3]. In the absence of diagnostic markers for early detection of the disease,
HBV-related HCC exhibits extremely poor prognosis, with median survival of less than 16
months [4]. Another well-established risk factor is excessive alcohol use. Studies have shown
that alcohol consumption significantly increases the risk of HCC in HBV-related patients [5].
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Multiple epidemiologic and pathologic studies have reported the synergism between alcohol
and HBV infection in the context of HCC [6–8]. Despite the recent advancements in the
knowledge of HCC and cancer in general, the molecular and transcriptional effects of ethanol
exposure on HCC pathogenesis and progression, and its specific effects in HCC with chronic
viral hepatitis B background, remain poorly characterized.
microRNAs (miRNAs) are a family of small non-coding RNAs that may significantly
enhance understanding of the specific functional effects, regulatory dynamics, and diagnostic,
prognostic and therapeutic considerations that may pertain to alcohol use in HBV+ HCCs [9,
10]. Discovered to modulate the expression of a broad array of protein-coding genes via post-
transcriptional regulation, miRNAs have been intensively studied as critical players in the car-
cinogenesis in many cancers, including HCC [11]. Several microRNAs, including miR-26 and
miR-122, have been found to be significantly associated with HCC progression and highly
associated with patient survival [12, 13]. In 2008, Budhu et al. reported a 20-miRNA metastasis
signature that could predict primary HCC with venous metastasis from metastasis-free solitary
tumors (p<0.001) [14]. However, to date, there have been no etiology-specific studies focusing
on the role of alcohol-regulated miRNAs in HCC pathogenesis and progression.
In this study, we sought to expand current understanding of the link between alcohol con-
sumption and HCC, using next-generation RNA-sequencing data from 130 HBV+ HCC
patients and 50 normal liver tissues. After performing a series of differential expression analy-
ses, we identified a panel of alcohol-associated miRNAs and subsequently investigated these
transcripts in vitro. Utilizing normal liver and established HCC cell cultures, we determined
that these candidate miRNAs, including miR-223-3p and miR-944, are directly modulated in
the presence of alcohol and acetaldehyde and are potentially involved in the early stages of
malignant transformation. Additionally, we evaluated how manipulating the expression of
miR-223-3p and miR-944 might induce changes in cellular proliferation, sensitivity to doxoru-
bicin, and the expression of both direct-binding and downstream mRNA targets. The results
of this study suggest that alcohol consumption in HBV+ HCCs regulates several miRNAs that
likely play previously uncharacterized roles in the alcohol-associated carcinogenesis of HCC.
Materials and methods
miRNA-sequencing datasets and clinical data
Level 3-normalized miRNA expression datasets and clinical data for 130 HCC patients and 50
tumor-adjacent normal liver tissues were obtained on 12 April 2016 from The Cancer Genome
Atlas (TCGA) (https://tcga-data.nci.nih.gov/tcga). Patients were separated into two cohorts
based on reported alcohol use and hepatitis B status in their clinical history: (1) Hepatitis B-
positive drinkers and (2) hepatitis B-positive nondrinkers. Patients with clinical history of hep-
atitis C, hemochromatosis, or non-alcoholic fatty liver disease were excluded from the analysis
to minimize confounding variables.Clinical characteristics for HCC patients used in this study
are provided in S1 Table.
miRNA differential expression analyses
miRNA read counts were extracted from the TCGA Level 3 gene expression files. The read
count tables were imported into edgeR v3.0 (http://www.bioconductor.org/packages/release/
bioc/html/edgeR.html) [15], and lowly expressed miRNAs (counts-per-million < 1 in more
than one-half of samples) were filtered from the analysis. Following TMM normalization, pair-
wise designs were applied to identify significantly differentially expressed miRNAs in (1) HCC
tumors from HBV+ drinkers versus normal liver tissue, (2) HCC tumors from HBV+ HCC
drinkers versus HCC tumors from HBV+ non-drinkers, and (3) HCC tumors from HBV
Alcohol-dysregulated microRNAs
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+ non-drinkers versus normal liver tissue. All miRNAs identified as differentially expressed in
each of the three edgeR comparisons were retained as candidates.
Association of candidate miRNAs with patient survival and somatic
mutations
Survival analyses were performed using the Kaplan-Meier Model, with miRNA expression in
HCC tumors designated as a binary variable based on expression above or below the median.
Mutation calls for the HCC tumors were obtained from mutation annotation files (maf) gener-
ated by the Broad Institute GDAC Firehose on 5 September 2016. We focused our analysis on
the 10 most frequently mutated genes in HCCs, as determined by Debuire et al. [16]. Wilcoxon
rank sum tests were employed to test for significant associations between miRNA expression
level (counts-per-million) and mutational status, as well as correlation with residual tumor
status.
Cell culture and treatments with ethanol and acetaldehyde
The non-cancerous liver cell line L02 as well as the human hepatoma cell line Hep3B were gifts
from the Wang lab at University of Hong Kong. The cells were cultured in DMEM supple-
mented with 10% fetal bovine serum, 2% penicillin/streptomycin, and 2% L-glutamate
(GIBCO) and maintained at 37˚C in a humidified 5% CO2/95% air atmosphere. These cells
were either exposed to ethanol for 7 days, or to acetaldehyde (Alfa Aesar) for 48 hours. The
dose used for ethanol treatment was chosen to be 0.1% by volume (17 mM) to represent social
drinking habits, as 0.1% is the blood alcohol level constituting legal intoxication in the U.S.
[17]. For all ethanol-culture experiments, treatment media was replaced every 24 hours with
fresh media containing the stated ethanol concentration. The tissue culture plates were also
sealed with paraffin film to reduce evaporative loss of ethanol from the media. It has been
shown that sealed culture vessels are able to maintain ethanol concentrations over significantly
longer incubation periods [18]. A concentration of 50 μM of acetaldehyde was used in acetal-
dehyde treatment to represent a range of light to heavy drinking as determined by the saliva
concentrations of alcohol consumers [19]. To account for the short evaporation half-life of
acetaldehyde, treatments were performed every 4 hours and the tissue culture plates were also
sealed with paraffin film.
Quantification of miRNA expression by qRT-PCR
Total RNA was isolated (Fisher Scientific) from cultured cells following treatment with ethanol
or acetaldehyde. cDNA was synthesized using the QuantiMiR™ RT kit (System Biosciences) as
per the manufacturer’s instructions. Real-time PCR reaction mixes were created using Fas-
tStart Universal SYBR Green Master Mix (Roche Diagnostics), and run on a StepOnePlus™
Real-Time PCR System (Applied Biosystems) using the following program: 50˚C for 2 min,
95˚C for 10 min, 95˚C for 30 s, and 60˚C for 1 min, for 40 cycles. Relative expressions of
mRNAs and miRNAs were calculated based on the RQ = 2^-ddCt method. U6 primers and a
Universal Reverse Primer were used from the QuantiMiR™ RT kit, and custom primers (Inte-
grated DNA Technologies) were ordered using the sequences listed in S2 Table.
Knockdown of miR-944 and miR-223-3p
L02 and Hep3B were transiently transfected with miR-944 and miR-223-3p inhibitors (Inte-
grated DNA Technologies) or control scramble sequences, using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA) according to manufacturer’s specifications.
Alcohol-dysregulated microRNAs
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AlamarBlue viability assay
L02 and Hep3B cells were plated in 96-well flat-bottom tissue culture plates (Falcon) at a den-
sity of 5,000 cells per well. Cells were transfected with the miRNA inhibitors 24 hours after
plating. After a 48-hour incubation period, cell viability was measured using an alamarBlue
Cell Viability Assay (ThermoFisher) in accordance with the manufacturer’s protocol. Fluores-
cence was measured using a SafireII plate reader (Tecan) at a wavelength of 590 nm.
MTS cell proliferation assays
L02 and Hep3B cells were plated in 96-well flat-bottom tissue culture plates (Falcon) at a den-
sity of 5,000 cells per well. For acetaldehyde experiments, cells underwent acetaldehyde treat-
ment as previously described, following a 24-hour plating period. At the 36-hour acetaldehyde
treatment time point, cells were transfected with the miRNA inhibitors. Cellular proliferation
was analyzed using an MTS proliferation assay (Promega) in accordance with the manufactur-
er’s protocol, beginning 24 hours after the last acetaldehyde treatment.
For doxorubicin sensitivity experiments, cells were transfected with the miRNA inhibitors
after a 24-hour plating period. They were subsequently exposed to one of several doses of
doxorubicin ranging from 0–4 μg/mL [20, 21]. After a 48-hour incubation period, cellular pro-
liferation was analyzed using an MTS proliferation assay (Promega). All assays were performed
in triplicate wells and experiments were individually performed at least twice.
g-H2AX Immunofluorescence
L02 and Hep3B were transfected with miR-944 and miR-223-3p inhibitors as previously
described and cultured on coverslips. Cells were subsequently treated with 0.25 μg/mL doxoru-
bicin for 48 hours, and were fixed with 4% paraformaldehyde and blocked in goat serum at
room temperature, followed by incubation with anti-phospho-Histone H2AX (JBW301)
mouse monoclonal antibody (Cell Signaling Technology). Cells were then incubated with
Alexa Fluor 594 donkey anti-mouse secondary antibody (Life Technologies) and counter-
stained with Hoechst. Immunofluorescence images were obtained at 40X using an inverted
fluorescence microscope.
g-H2AX foci scoring
g-H2AX foci were quantified using the CellProfiler program (http://cellprofiler.org/). For each
sample, the average number of g-H2AX foci per cell was determined using at least 3 images
taken from different fields on the coverslip (containing60 nuclei total). Statistical signifi-
cance was assessed using Student’s t-test.
Identification and qRT-PCR verification of miR-944 and miR-223-3p
target genes
Putative mRNA targets of miR-944 and miR-223-3p were selected using the TargetScan (v6.2)
(http://www.targetscan.org/), miRanda (v15.0) (http://www.microrna.org/microrna/home.
do), miRmap (v15.0) (http://mirmap.ezlab.org) and miRDB (v1.1) (http://mirdb.org/miRDB/)
target prediction algorithms based on miRNA seed region complementarity in the mRNA
3’UTR.
Total RNA was collected from L02 and Hep3B 48 hours after transfection with miR-944
and miR-223-3p inhibitors. cDNA was synthesized using M-MLV Reverse Transcriptase
(Promega) and qRT-PCRs were performed as previously described, with GAPDH serving as
Alcohol-dysregulated microRNAs
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endogenous control. Primers for the target genes were custom synthesized (Eurofins MWG
Operon) using the following sequences and their sequences are listed in S3 Table.
Results
Identification of miRNAs dysregulated by alcohol consumption in HBV
patients
We obtained clinical and microRNA-sequencing data containing normalized expression of
1,046 miRNAs for 130 HCC patients and 50 normal liver tissues from the TCGA database on
12 April 2016. In order to capture the miRNAs specifically dysregulated by alcohol in HBV
patients, only patients with (1) HBV infection and (2) no history of conditions other than
HBV and/or chronic alcohol consumption were selected. Using these patients, two cohorts
were created: drinker HBV+ patients and non-drinker HBV+ patients. A total of three differ-
ential comparisons were performed: (1) HBV+ HCC drinkers versus normal liver; (2) HBV
+ HCC drinkers versus HBV+ HCC non-drinkers; (3) and HBV+ HCC non-drinkers versus
normal liver (Fig 1A). Using negative binomial-based differential expression testing, we identi-
fied a panel of 48 miRNAs that are significantly dysregulated between HBV+ drinker and
HBV+ nondrinker HCC tumors. In particular, 5 miRNAs (miR-9-1, miR-9-2, miR-223, miR-
944, and miR-153) were found to be significantly dysregulated (Fig 1B, Table 1), establishing
themselves as associated with both alcohol drinking status and HCC tumor vs. adjacent nor-
mal tissue status. Among these, 2 miRNAs (miR-223 and miR-944) also showed strong corre-
lation with genomic alterations and clinical indications associated with HCC. Notably, miR-
944 expression significantly correlated with incidence of mutated CTNNB1 (p = 0.019) (Fig
1C), a well-studied proto-oncogene [22], in HCC tumors; and miR-223 expression signifi-
cantly correlated with presence of residual tumor after treatment (p = 0.037) (Fig 1D) and with
univariate patient survival (p = 0.016) (Fig 1E).
In vitro acetaldehyde and alcohol treatment validates alcohol-induced
microRNA expression
To validate that our selected miRNAs play a role in the alcohol-associated pathogenesis of
HCC, we performed in vitro ethanol treatment using the normal liver cell line L02 and the
HCC cell line Hep3B, derived from an HBV+ HCC patient. The cells were treated with 0.1%
(17 mM) alcohol by volume once a day for 7 days, mimicking the blood alcohol level attained
by social drinkers [18]. An MTS assay showed that there were no significant changes in cell
survival in LO2 and Hep3B cells treated with ethanol (S1 Fig). Following alcohol treatment,
two miRNAs (miR-223 and miR-944), previously identified to be overexpressed in HCC
drinkers, were significantly upregulated in both L02 and Hep3B, with over 5-fold increase in
miR-944 expression in both cell lines. Additionally, two miRNAs (miR-9 and miR-153-2-3p),
previously identified to be downregulated in HCC drinkers, were inhibited in both cell lines
upon alcohol treatment (Fig 2A).
Since ethanol metabolism by hepatocytes is thought to be the basis behind the pathogenesis
of HCC in alcohol-consuming patients, we also treated our cell lines with acetaldehyde, the
first and carcinogenic metabolite of ethanol. An MTS assay showed that there were no signifi-
cant changes in cell survival in LO2 and Hep3B cells treated with acetaldehyde (S1 Fig). RT-
qPCR revealed that when liver cell lines were exposed to physiologically relevant doses of acet-
aldehyde (50 uM) [19] continuously for 48 hours, significant dysregulation was observed in
the expression of all four miRNAs (miR-223 and miR-944, miR-9, miR-153-2) (Fig 2B). Taken
together, our data suggests that dysregulation of these miRNAs is due to alcohol metabolism,
Alcohol-dysregulated microRNAs
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and may be an early event in the malignant transformation of liver cells, underscoring the
importance of further investigating these miRNAs to better understand their roles in HCC.
Knockdown of miR-944 and miR-223 decreases liver cell proliferation
and mitigates the effect of acetaldehyde
The two microRNAs, namely miR-223-3p and miR-944, were selected for further functional
analysis as they showed the most consistent dysregulation in the sequencing analyses, correla-
tion with clinical characteristics, and validated expression in vitro. miR-223-3p, instead of -5p,
was chosen, as it was the more abundantly detected strand in the miRNA-sequencing data,
and has been implicated in multiple studies in HCC and alcohol [23, 24]. To functionally char-
acterize the effects of these two miRNAs, we investigated their influence on cell viability and
cellular proliferation. Upon suppression of miR-223-3p and miR-944 using siRNAs, cell viabil-
ity and cellular proliferation were significantly inhibited in both L02 and Hep3B within 96
hours, with nearly 2-fold decrease in both cell lines for miR-223-3p (Fig 3A and 3B). In addi-
tion, our results show that knockdown of the two miRNAs is capable of mitigating the effect of
acetaldehyde by inhibiting cell growth. Acetaldehyde, being both carcinogenic and cytotoxic,
was observed to inhibit cell growth at 50 uM in this study. When cells were treated with acetal-
dehyde and were simultaneously transfected with miRNA inhibitors, consistent decrease in
Fig 1. RNA-sequencing analysis identifies miRNAs that are dysregulated due to alcohol consumption
in HBV-affected patients. (A) Schematic illustrating the analysis approach employed in this study. (B) Heat
map depicting 48 miRNAs that are significantly dysregulated in at least two of the three comparisons
(FDR < 0.05): nondrinker HBV+ vs normal, drinker HBV+ vs normal, drinker HBV+ vs non-drinker HBV+ (from
left to right). (C) Boxplot showing significant correlation in expression level of miR-944 and somatic mutations
of CTNNB1 in HBV-associated HCC tumors. (D) Boxplot exhibiting significant correlation between miR-223
expression and patients’ tumor status following treatment. (E) Kaplan-Meier curves showing survival
outcomes in HBV-affected HCC patients stratified by the expression level of miR-223.
https://doi.org/10.1371/journal.pone.0178547.g001
Alcohol-dysregulated microRNAs
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cell proliferation was observed in both cell lines for both miRNAs compared to cells treated
with acetaldehyde alone (Fig 3C).
Inhibition of miR-223-3p and miR-944 sensitizes cells to doxorubicin-
induced DNA damage and cell death
To further explore the functional significance of miR-223-3p and miR-944, we tested their
ability to sensitize cells to doxorubicin, a chemotherapy drug commonly utilized in treating
HCC [25]. Our results indicate that knockdown of miR-223-3p and miR-944 promotes doxo-
rubicin-mediated cell death (Fig 4A), with the IC50 for doxorubicin reduced by 52% and 71%,
respectively, in L02. In Hep3B, while the difference in IC50 was modest, the effect of miRNA
knockdown on cell death was remarkable at higher doses, where complete cell death was only
achieved following miRNA knockdown (Fig 4B). Additionally, we assessed the effects of miR-
223-3p and miR-944 on apoptotic DNA fragmentation at 0.25 ug/ml doxorubicin using the
DNA double-strand break and apoptosis marker γ-H2AX. Immunofluorescence showed sig-
nificant upregulation of punctate γ-H2AX foci in miR-223-3p and miR-944-knockdown cell
lines treated with doxorubicin (Fig 4C), with miR-223-3p-knockdown doxorubicin-treated
L02 and miR-944-knockdown doxorubicin-treated Hep3B exhibiting more than 2-fold induc-
tion of γ-H2AX foci compared to cells treated with doxorubicin alone (Fig 4D).
Next, to further examine the increased sensitivity to doxorubicin imparted by miR-944 and
miR-223-3p, we evaluated the expression of a panel of key apoptosis genes following miRNA
knockdown at 0.25 ug/ml doxorubicin. Notably, p73 showed significant upregulation follow-
ing miR-944 knockdown, with over 3-fold increase in expression in both cell lines. Apoptotic
inhibitor Survivin, a direct target of Wnt pathway and a negative regulator of caspase, was
found to be inhibited for miR-944 and miR-223-3p in both cell lines. Additionally, XIAP,
Table 1. List of microRNAs that are significantly dysregulated in HBV+ HCC drinkers.
Drinker HCC versus Non-drinkers HCC
Fold change logCPM P values
hsa-mir-223 2.99 7.45 1E-08
hsa-mir-9-1 -4.54 9.20 2E-03
hsa-mir-9-2 -4.53 9.19 2E-03
hsa-mir-153-2 -3.03 3.59 2E-03
hsa-mir-944 3.12 1.51 4E-03
Non-drinkers HCC versus Normal
Fold change logCPM P values
hsa-mir-223 -1.80 7.31 1E-08
hsa-mir-9-1 13.03 8.99 3E-17
hsa-mir-9-2 12.95 8.99 3E-17
hsa-mir-153-2 1.38 3.74 1E-01
hsa-mir-944 2.84 1.06 1E-05
Drinker HCC versus Normal
Fold change logCPM P values
hsa-mir-223 1.77 8.22 6E-03
hsa-mir-9-1 3.42 6.85 1E-10
hsa-mir-9-2 3.39 6.84 1E-10
hsa-mir-153-2 -1.97 3.24 3E-06
hsa-mir-944 7.17 1.31 2E-11
https://doi.org/10.1371/journal.pone.0178547.t001
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another apoptotic inhibitor gene, also showed strong downregulation following miR-944
knockdown (Fig 5A).
Prediction and PCR validation of mRNA targets for miR-223-3p and miR-
944
To further define molecular roles for miR-223-3p and miR-944, we utilized four different
computational programs (miRDB, TargetScanHuman, miRanda and miRmap) in searching
for the putative target for the two miRNAs [26–29]. To avoid bias generated by the individual
algorithms, only the targets that were commonly proposed in all four of the programs were
selected. To validate these targets, we evaluated the expression levels of these putative targets
following knockdown of miR-944 and miR-223-3p down the miRNAs in liver cell lines. Inhi-
bition of miR-223-3p induced significant upregulation of Fbxw7, a tumor suppressor that has
been previously reported to correlate with HCC prognosis and found to be consistently
reduced in HCC tumors and cell lines [30–32]. Moreover, inhibition of miR-944 significantly
Fig 2. Ethanol and acetaldehyde treatment in liver cells verifies clinical data analysis in miRNAs expression. (A) qRT-PCR
demonstrates that 7-day ethanol treatment dysregulates the expression level of 6 miRNAs in both Hep3B and L02. (B) qRT-PCR
demonstrates that 48-hour acetaldehyde treatment dysregulates the same set of miRNAs in both cell lines. All bar graphs are presented as
the mean and error bars representing standard deviations. *p<0.05, **p<0.01, ***p<0.001, Student’s t-test.
https://doi.org/10.1371/journal.pone.0178547.g002
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upregulated both HECW2 and KIAA1109 (Fig 5B). The putative seeding regions between
microRNAs and mRNAs are depicted in Fig 5C.
Discussion
Despite substantial evidence implicating alcohol use as both an independent risk factor and
cofactor in HCC [33], there remains a limited understanding of how alcohol directly promotes
HCC pathogenesis and progression, and how alcohol operates in conjunction with other risk
factors such as HBV infection, the most prevalent etiological agent for HCC [3]. Previous stud-
ies, although identifying key enzymes and signaling pathways compromised by hepatic ethanol
metabolism [34, 35], have only sparsely examined alcohol-induced changes at the gene expres-
sion and transcriptional levels as they relate to the development of HCC. Thus, in this study,
we sought to enhance knowledge of the contribution of alcohol exposure to HCC, by identify-
ing and functionally characterizing miRNAs regulated by alcohol in HBV+ HCCs.
We are the first to undertake a focused investigation of the expression patterns of alcohol-
associated miRNAs in HCC. Through a series of RNA-sequencing analyses of 130 HBV+ HCC
patients from the TCGA database, stratified by drinking status, we identified 5 miRNAs (miR-
9-1, miR-9-2, miR-153-2, miR-223, and miR-944) differentially expressed by more than 2-fold
Fig 3. Inhibition of miR-944 and miR-223-3p inhibits cell viability and cell proliferation. (A) AlamarBlue cell viability assays evaluate
the change in cell viability in L02 and Hep3B at 48, 72 and 96 hours after miR-944 and miR-223-3p knockdown. (B-C) Knockdown of miR-
944 and miR-223-3p significantly inhibits cell proliferation in both the absence (B) and the presence (C) of acetaldehyde.
https://doi.org/10.1371/journal.pone.0178547.g003
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in chronic alcohol drinkers with HBV+ HCC in comparison to nondrinkers with HBV+ HCC.
Consistent with previous HCC miRNA profiling studies [36–38], miR-9-1 and miR-9-2 were
overexpressed in HBV+ HCC tumors relative to normal tissue; however, miR-9-1 and miR-9-
2 were significantly downregulated in tumors from HBV+ HCC drinkers relative to tumors
from HBV+ HCC non-drinkers (Fig 1B and Table 1). A previous study in fetal neural stem
cells revealed that miR-9 and other miRNAs may be subject to coordinate or even opposing
Fig 4. Inhibition of miR-944 and miR-223-3p enhances doxorubicin-induced cell death and DNA
damage. (A-B) MTS assay indicates that miR-944 and miR-223-3p knockdown sensitizes liver cells to
doxorubicin, as shown by the reduction in doxorubicin IC-50. (C-D) Immunofluorescence images showing
increased expression of γ-H2AX in cells treated with both doxorubicin and miRNA siRNAs compared to cell
treated with doxorubicin alone. Cells were stained with anti-γH2AX (red) and DAPI (blue).
https://doi.org/10.1371/journal.pone.0178547.g004
Fig 5. miR-944 and miR-223-3p knockdown in HCC cell lines upregulates predicted target tumor suppressor genes, and induces
changes in key apoptosis gene expression. (A) Knockdown of miR-223-3p and miR-944 alters key apoptosis gene expression in Hep3B
and L02. (B) Inhibition of miR-944 significantly upregulates both HECW2 and KIAA1109; and inhibition of miR-223-3p significantly
upregulates Fbxw7. (C) Putative seeding regions between the mature miRNAs and target mRNAs are presented.
https://doi.org/10.1371/journal.pone.0178547.g005
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regulation following concurrent exposure to ethanol and nicotine, resulting in greater disrup-
tion to miRNA regulatory networks [39]. Further exploration of whether a similar interplay
exists in HCC between alcohol use and HBV infection, in the context of regulating miR-9 and
the other alcohol-associated HCC miRNAs we have identified, may be merited. Additionally,
we found that miR-153-2 is upregulated relative to normal liver in HBV+ HCC non-drinkers,
but downregulated in HBV+ HCC drinkers (Fig 1B and Table 1). Previously, Xia et al.
reported that miR-153 suppresses epithelial-mesenchymal transition in HCCs [40], while Hua
et al. and Chen et al. reported that miR-153 activates Wnt/β-catenin [41] and promotes resis-
tance to chemotherapy and small molecular kinase inhibitors in HCC [42]. Our finding that
the divergent expression and regulation of miR-153 may be dictated by exposure to alcohol
may provide a means of resolving these conflicting studies of miR-153 expression and function
in HCCs. We also observed downregulation of miR-223 in non-drinker HBV+ HCCs, and
upregulation of miR-223 in drinker HBV+ HCCs, relative to normal tissue (Fig 1B and
Table 1), a result which may similarly contribute to our understanding of what has previously
appeared to be discrepant patterns of miR-223 expression in HCCs [24, 43, 44]. Meanwhile, to
our knowledge, we are the first to report upregulation of miR-944 in HCC, and in drinkers
with HCC relative to nondrinkers (Fig 1B and Table 1), although previous studies of miR-944
in have demonstrated its consistent upregulation in cervical and breast cancers [45, 46]. Our
identification of a novel panel of miRNAs in HCCs linked to chronic alcohol exposure, cou-
pled with our analyses correlating miR-944 with mutations in Wnt-activator CTNNB1 [22]
and miR-223 with patient survival and presence of residual tumor (Fig 1C–1E), suggests that
alcohol-mediated dysregulation of miRNAs in HBV+ HCC modulates central pathways and
contributes to clinically relevant phenotypes in HCC patients. In addition to showing that
HBV+ HCC tumors assume miRNA expression profiles distinguishable by drinking history,
our analyses also provide a complement to existing studies profiling hepatitis-associated miR-
NAs in HCC [47–50] and hepatitis- and alcohol-regulated miRNAs in cirrhosis and fatty liver
disease [51–53]. In this context, our study contributes to a composite understanding of HCC
not only as a malignancy in isolation but as part of a lineage of chronic liver diseases.
We found miR-9, miR-153-2, miR-223, and miR-944 to be dysregulated in normal cell line
L02 and HBV+ HCC cell line Hep3B following treatment with physiologically relevant doses
of ethanol and acetaldehyde [19], demonstrating that altered expression of these miRNAs is
indeed directly caused by alcohol exposure, and likely involved in the early stages of HBV
+ hepatic carcinogenesis. As acetaldehyde treatment alone also proved sufficient to differen-
tially regulate these miRNAs, our results further corroborate the premise that the metabolism
of ethanol to acetaldehyde is at least partially responsible for alcohol-associated HCC [34, 35].
In particular, we found that siRNA-mediated knockdown of miR-944 and miR-223-3p signifi-
cantly decreased proliferation of L02 and Hep3B (Fig 3B), as well as the proliferation of L02
and Hep3B treated with acetaldehyde (Fig 3C). This potential of miR-944 and miR-223-3p to
regulate cellular proliferation under both conditions suggests that the suppression of these
miRNAs may be utilizable in preventing or mitigating the specific effects of alcohol and acetal-
dehyde in hepatocytes. In addition, we observed that miR-944 and miR-223-3p knockdown
significantly sensitized L02 and Hep3B to doxorubicin (Figs 4A, 4B and 5A). As evidenced by
relative accumulation of γ-H2AX foci, miR-944 and miR-223-3p inhibition potentiated doxo-
rubicin-induced DNA double-strand breaks in L02 and Hep3B (Fig 4C). Notably, suppression
of both miRNAs in doxorubicin-treated L02 and Hep3B also reduced mRNA levels of Survi-
vin, an apoptotic inhibitor extensively associated with HCC proliferation [54], progression
[55], and patient prognosis [56] (Fig 5A). miR-944 knockdown additionally restored expres-
sion of p73 and suppressed expression of XIAP (Fig 5A). Collectively, these findings suggest
that miR-944 and miR-223-3p may represent possible therapeutic candidates that can be
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leveraged to overcome chemoresistance in HCC; previously, miR-944 and miR-223 were
found to regulate cisplatin resistance in breast cancer and gastric cancer, respectively [46, 57].
The genes we have identified to be putative targets of miR-944 and miR-223-3p in alcohol-
associated HCC further substantiate our proposed functions for these miRNAs as well. miR-
944 was found to negatively regulate KIAA1109 (Fig 5B), a gene newly associated with cancer
risk and found to be recurrently mutated in pan-cancer studies [58, 59]; as well as HECW2
(Fig 5B), a ubiquitin ligase established as a direct target of miR-944 in cervical tumors [45].
HECW2 has also been reported to stabilize and enhance p73 transcriptional activity [60], con-
sistent with our findings of p73 induction following miR-944 knockdown in doxorubicin-
treated cell lines (Fig 5A). However, further research on the specific roles of KIAA1109,
HECW2, and p73 in HCC is warranted. Meanwhile, miR-223-3p was found to target Fbxw7
(Fig 5B), a cell cycle regulator that promotes c-Myc and cyclin E degradation [61], suggesting
that the well-documented miR-223/Fbxw7 axis [62, 63] is functionally active in HCC, in addi-
tion to modulating resistance to γ-secretase inhibitor treatment in leukemia [64] and resis-
tance to cisplatin in gastric cancers [57]. In the context of HCC, Fbxw7 has already been found
to be significantly downregulated in tumors compared to normal liver, with both mRNA and
protein expression correlating with tumor stage, histological grade and disease-free survival
[32, 61]. Future studies examining with greater resolution the possible dependence of these
pathways on alcohol exposure in HBV+ HCC, and their potential involvement as downstream
effectors of miR-944 and miR-223-induced changes to chemoresistance and apoptotic
response, promise to add a new layer of insight into the alcohol-associated miRNA regulatory
dynamics of HCC.
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